Literature DB >> 7952197

Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis.

T T Ng1, G D Robson, D W Denning.   

Abstract

Aspergillus fumigatus and Aspergillus flavus are the most common cause of invasive mould infections worldwide and carry a high mortality. Corticosteroid therapy and Cushing's disease are associated with an increase in invasive aspergillosis. Corticosteroids impair immune function in mammals and, specifically, the conidicidal activity of human macrophages, which was thought to be sufficient explanation for this increased risk. However, we have found a 30-40% increase in growth rate of A. fumigatus and A. flavus exposed to pharmacological doses of hydrocortisone (a human glucocorticoid), suggesting an alternative or additional mechanism for the association. No significant effect was observed with other human steroids such as testosterone, oestradiol or progesterone, though a smaller (21%) but significant growth rate increase was obtained with the fungal sterol ergosterol. The presence of a ligand/receptor system is therefore possible in pathogenic Aspergillus spp. Although corticosterone-binding proteins have been identified in some yeast species, a demonstrable physiological effect has been lacking. Interruption of the putative ligand/receptor interaction could have a major effect on the growth and pathogenicity of A. fumigatus, providing opportunities for the development of alternative therapeutic strategies to those currently available.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7952197     DOI: 10.1099/13500872-140-9-2475

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


  46 in total

1.  What can we learn and what do we need to know amidst the iatrogenic outbreak of Exserohilum rostratum meningitis?

Authors:  Dimitrios P Kontoyiannis; David S Perlin; Emmanuel Roilides; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2013-05-06       Impact factor: 9.079

Review 2.  Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species.

Authors:  Sharon C-A Chen; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Virulence       Date:  2011-07-01       Impact factor: 5.882

3.  Immunity status of invasive pulmonary aspergillosis patients with structural lung diseases in Chinese adults.

Authors:  Shuo Liang; Rong Jiang; Hai-Wen Lu; Bei Mao; Man-Hui Li; Cheng-Wei Li; Shu-Yi Gu; Jiu-Wu Bai; Jin-Fu Xu
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

4.  In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.

Authors:  K L Oakley; C B Moore; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 5.  Virulence factors of medically important fungi.

Authors:  L H Hogan; B S Klein; S M Levitz
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 6.  Allergic bronchopulmonary aspergillosis.

Authors:  Richard B Moss
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

7.  Invasive pulmonary aspergillosis in acute exacerbation of chronic obstructive pulmonary disease and the diagnostic value of combined serological tests.

Authors:  Xiaofang Gao; Liangan Chen; Guangrong Hu; Haiyu Mei
Journal:  Ann Saudi Med       Date:  2010 May-Jun       Impact factor: 1.526

8.  In vivo bioluminescence imaging and histopathopathologic analysis reveal distinct roles for resident and recruited immune effector cells in defense against invasive aspergillosis.

Authors:  Oumaïma Ibrahim-Granet; Grégory Jouvion; Tobias M Hohl; Sabrina Droin-Bergère; François Philippart; Oh Yoen Kim; Minou Adib-Conquy; Reto Schwendener; Jean-Marc Cavaillon; Matthias Brock
Journal:  BMC Microbiol       Date:  2010-04-08       Impact factor: 3.605

9.  Assessment of the significance of respiratory culture of Aspergillus in the non-neutropenic patient. A critique of published diagnostic criteria.

Authors:  R C Barton; R P Hobson; H McLoughlin; A Morris; B Datta
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-01       Impact factor: 3.267

Review 10.  Management of invasive aspergillosis in patients with COPD: rational use of voriconazole.

Authors:  Florence Ader; Anne-Lise Bienvenu; Blandine Rammaert; Saad Nseir
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.